Background: Many critically ill patients treated in the intensive care unit (ICU) experience sleep disruption. Midazolam is commonly used for the sedation of critically ill patients. This pilot study is aimed to identify the optimal dose of midazolam for achieving sound sleep in critically ill patients. Methods: This prospective study was conducted in the medical ICU of a tertiary referral hospital. Polysomnography recording was performed over 24 hours to assess the quantity and quality of sleep in patients sedated with midazolam. 
Introduction
Sleep is an essential factor for healthy life. [1, 2] However, many critically ill patients are known to experience sleep deprivation. [3, 4] They have poor sleep quality characterized by suppressed slow wave sleep (SWS) and rapid eye movement (REM) sleep because their sleep is interrupted frequently, regardless of normal total sleep time (TST). [5] The cause of sleep deprivation is not clearly understood, but multiple factors including noise, [6] bright light, inflammatory mediators, [4] tests such as blood sampling, taking vital signs [7] and mechanical ventilation, [8] appear to cause sleep disruption in intensive care unit (ICU) patients. Sleep deprivation can lead to the deterioration in neurocognitive performance, [9] immune function [10] and respiratory control, [11] posing a serious barrier to effective intensive care.
ICU patients are commonly treated with sedatives to reduce pain, relieve anxiety and induce sleep. [12] Midazolam is one of the most commonly used sedatives in ICU settings. [13] As a gamma-aminobutyric acid (GABA) receptor-specific drug, midazolam is metabolized in the liver and excreted through the kidney with the elimination half life of 3 hours. [14] Even many researches were explored sedative effects of midazolam on ICU pa- This study aimed to examine the association of intravenous midazolam infusion at different doses with sleep quantity and quality in ICU patients using 24-hour polysomnography (PSG) and to determine an appropriate dose of midazolam for Korean ICU patients. 
Materials and Methods

1) Study population
2) Polysomnography (PSG)
The quantity and quality of sleep of patients were measured for 24 hours using Somnowatch™, plus (SOMNOmedics, Rander- 
3) Statistical analysis
Medians and interquartile range (IQR) were used to describe continuous variables, and percentages (%) were used to express baseline characteristics, such as sex, diagnosis, and survival rate.
Sleep efficiency (%) was calculated as the ratio of TST to total time of lying down. [20] Wake index (n/h) was defined as the number of awakenings per hour. Spearman's correlation was used to detect the association between midazolam dose and TST and the association between midazolam dose and sleep stages (REM, non-REM Level 1, 2, 3) and identify a specific sleep stage that is most affected by the sedative. p values less than 0.05 were considered statistically significant. The software package SPSS version 21.0 (IBM Corporation, Armonk, NY, USA) was used to analyze the data.
Results
Of 20 patients who underwent PSG for 24 hours during the study period, nine of them received midazolam as sedative by continuous infusion for 24 hours. Of those, three patient's PSG data could not be interpreted because of severe artifacts, and one patient who received 0.08 mg/kg/h of intravenous midazolam was found to be coma in PSG. Therefore, PSG recordings of five patients were analyzed in this study. Baseline patient characteristics are summarized in Table 1 . The median patient age, APACHE II and SOFA score was 67, 20 and 6, respectively. The median ICU length of stay was 3.0 days at the time of PSG test. PSG data of the five patients were summarized in Table 2 .
Median TST was 494 min, and the median amount of REM was Sleep deprivation also affects muscles of respiration, which not only lowers tidal volume [29] but also makes respiratory response to carbon dioxide slow. [30] In this case, weaning from mechanical ventilation can be difficult. [4] In this study, the low-dose of Hypersomnia is well known to disrupt circadian rhythm and contribute to the increasing mortality rate. [1] In this study, the patients showed an adequate amount of TST This pilot study had a several limitations. It could not provide further analysis of the relationship between sleep and clinical indicators such as RASS and carbon dioxide concentration due to small sample size. We also used remifentanyl, which can inhibit REM sleep, [33] to manage pain of the patients because they were undergoing tracheal intubation and mechanical ventilation.
Remifentanyl may be partly responsible for their decreasing REM sleep.
In conclusion, we found continuous intravenous infusion of of intensivists seem important to achieve desired results.
